Exacerbation of undiagnosed mycosis fungoides during treatment with etanercept

Archives of Dermatology

Volumn 145, Issue 1, 2009, Pages 94-95

  Lafaille, Philippe ^a   Bouffard, Danielle ^b   Provost, Nathalie ^b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BEXAROTENE; ETANERCEPT; METHOTREXATE; PSORALEN;

ADULT; CANCER RADIOTHERAPY; CASE REPORT; DIAGNOSTIC ERROR; DISEASE EXACERBATION; HUMAN; HUMAN TISSUE; LETTER; MALE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; PSORIASIS; SKIN BIOPSY; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

ARTHRITIS, PSORIATIC; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; RECEPTORS, TUMOR NECROSIS FACTOR; SKIN NEOPLASMS;

EID: 58849113920     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2008.526     Document Type: Letter

References (5)

1. Langley RG, Keystone EC, Bissonnette R, Papp Kim A. Long term safety of etanercept. J Cutan Med Surg. 2007;11(suppl 1):S23.
2. Schmidt A, Robbins J, Zic J. Transformed mycosis fungoides developing after treatment with alefacept. J Am Acad Dermatol. 2005;53(2):355-356.
3. Dalle S, Balme B, Berger F, Hayette S, Thomas L. Mycosis fungoides-associated follicular mucinosis under adalimumab. Br J Dermatol. 2005;153(1):207-208.
4. Adams AE, Zwicker J, Curiel C, et al. Aggressive cutaneous T-cell lymphomas after TNFa blockade. J Am Acad Dermatol. 2004;51(4):660-662.
5. van Vollenhoven RF. Benefits and risks of biological agents: lymphomas. Clin Exp Rheumatol. 2004;22(5)(suppl 35):S122-S125.